NASDAQ · AVIR
Atea Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AVIR: Nov 11, 2026
Atea Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.5. The reported EPS for the same quarter last year was $-0.53.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.50 | $-0.42 | $-0.59 | 2 |
| Dec 2026 | $-0.57 | $-0.42 | $-0.72 | 2 |
| Mar 2027 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Jun 2027 | $-0.45 | $-0.45 | $-0.45 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · RTTNews · Zacks- The Motley Fool · Aug 19, 5:13 PM EDTAtea (AVIR) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 6:04 PM EDTAtea Pharmaceuticals Q2 Earnings Call HighlightsAtea Pharmaceuticals (NASDAQ:AVIR) reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, m
- RTTNews · Jun 26, 3:36 AM EDTAtea Completes Patient Enrollment In Phase 3 C-FORWARD Trial In Hepatitis C(RTTNews) – Atea Pharmaceuticals, Inc. (AVIR) a late-stage clinical biopharmaceutical company announced the completion of patient enrollment in its Phase 3 C-FORWARD trial evaluating Bemnifosbuvir and Ruzasvir in the treatment of Hepatitis C virus infection outside North America.
- Zacks · Jun 18, 12:00 PM EDTAtea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should KnowAtea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Jun 9, 9:40 AM EDTAre Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
- Zacks · May 15, 9:35 AM EDTDown 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a TurnaroundAtea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the nea
- MarketBeat · May 12, 6:08 PM EDTAtea Pharmaceuticals Q1 Earnings Call HighlightsAtea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options. During the company’s first-quarter 2026 earnings call,
- Fintel · Apr 29, 12:42 AM EDTAtea Pharmaceuticals (AVIR) Price Target Increased by 25.00% to 10.20The average one-year price target for Atea Pharmaceuticals (NasdaqGS:AVIR) has been revised to $10.20 / share. This is an increase of 25.00% from the prior estimate of $8.16 dated April 12, 2026. The price target is an average of many targets provided by analy
- Fintel · Mar 27, 12:56 AM EDTAtea Pharmaceuticals (AVIR) Price Target Increased by 33.33% to 8.16The average one-year price target for Atea Pharmaceuticals (NasdaqGS:AVIR) has been revised to $8.16 / share. This is an increase of 33.33% from the prior estimate of $6.12 dated February 21, 2026. The price target is an average of many targets provided by ana
- The Motley Fool · Mar 5, 6:00 PM ESTAtea Pharma (AVIR) Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Dec 23, 2:19 AM ESTAtea Completes Enrollment In C-BEYOND Hepatitis C Trial; Data Due In Mid-2026(RTTNews) – Atea Pharmaceuticals Inc. (AVIR) has completed patient enrolment in its pivotal North American Phase 3 trial, dubbed C-BEYOND, evaluating the fixed-dose combination of Bemnifosbuvir and Ruzasvir for the treatment of hepatitis C virus.
- The Motley Fool · Aug 7, 5:33 PM EDTAtea (AVIR) Q2 Loss Narrows 8%GAAP EPS of $0.44 for Q2 2025 was narrower than the estimated loss and improved over last year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Atea Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.